Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 34Cyclophosphamide 31Peripheral Blood Stem Cell Transplantation 27Mycophenolic Acid 25Cyclosporine 23Antilymphocyte Serum 23Busulfan 20Tacrolimus 17Radiotherapy 17Filgrastim 17Whole-Body Irradiation 15Methotrexate 15Methylprednisolone 14Melphalan 13Cord Blood Stem Cell Transplantation 12venetoclax 9Cytarabine 8Azacitidine 8fludarabine 5Etoposide 5sargramostim 4Therapeutics 4Sirolimus 4Decitabine 4Clofarabine 4Alemtuzumab 4thymoglobulin 3nilotinib 3merphos 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × devimistat × Myeloid × Clear all
NCT01520805 2016-12-29

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡